Podcast

Handing a Piece of Life Back

Author(s):

Kristie L. Kahl

Laurie was no stranger to cancer after she faced a bout with stage 3b non-Hodgkin lymphoma back in 1977, but her second diagnosis of breast cancer left her with a very tough decision on how she wanted to move forward with treatment.

Laurie was no stranger to cancer after she faced a bout with stage 3b non-Hodgkin lymphoma back in 1977, but her second diagnosis of breast cancer left her with a very tough decision on how she wanted to move forward with treatment.

After her oncologist recommended she us a diagnostic test, called the Oncotype DX assay, that helps make informed, individualized treatment decisions, Laurie was able to forgo chemotherapy treatment when she received a recurrence score that indicated that she had a relatively low risk of her cancer returning.

This week, we spoke with Laurie about her treatment decisions, and how this diagnostic test gave her what she calls “a piece of her life back.”

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Evens.
Image of carly.
Image of kelly.
Image of doctor.
Image of Dr. Kelly
image of doctor D'Sa
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Image of woman with brown hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Related Content
The ADC zilovertamab vedotin plus Rituxan and chemo showed an ORR of 56.3% in relapsed/refractory DLBCL: © stock.adobe.com.
June 9th 2025

Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL

Silas Inman
The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of blood.
June 7th 2025

KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety

Kristi Rosa
The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Linda Cohen is a survivor of small lymphocytic lymphoma and was diagnosed in 2009. Catch up on all of Linda's blogs here!
June 3rd 2025

You Are Not a Statistic: Facing Cancer With Hope, Not Numbers

Linda Cohen
I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story than the statistics.
The phase 1/2 STARLIGHT-1 trial evaluating EB103 has dosed the first patient with advanced B-cell NHL: © stock.adobe.com.
May 30th 2025

First Patient Treated in Second Cohort of STARLIGHT-1 B-Cell NHL Trial

Ryan Scott
The phase 1/2 STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell non-Hodgkin’s lymphomas.